Miorel (Thiocolchicoside) is commonly used to provide symptomatic relief in situations involving certain distressing symptoms, such as symptoms of increased neurological or muscular activity that may interfere with daily functioning. It is generally applied in contexts where additional symptomatic support is needed to address pronounced muscle stiffness and associated pain.

The systemic form may be part of symptomatic management as adjuvant treatment of painful muscle contractures in acute spinal pathology in patient groups including adults and adolescents 16 years and older. This medication is considered relevant for managing conditions presenting with acute episodes, such as low back pain, cervicalgia (neck pain), or torticollis.

“This medication contributes to improved comfort during periods of heightened symptoms and supports patients during difficult episodes.”

In managing the symptoms related to stiffness, the medication offers symptomatic relief that helps patients cope more steadily. This may assist with maintaining functional stability and supports the patient by easing the distress caused by restricted mobility.

Quick Fact: Relief for Acute Muscular Contractures Thiocolchicoside is commonly used to help manage painful muscular contractures, which are often associated with acute spinal conditions.

The eligibility profile for Miorel (Thiocolchicoside) strictly defines which populations may use the medicine based on regulatory assessment.

Populations for Whom Use is Contraindicated

Use is absolutely prohibited for pregnant women and women who are breastfeeding or lactating. This prohibition also extends to women of childbearing potential who are not using effective contraceptive measures. The medicine is also contraindicated in patients with a known hypersensitivity to Thiocolchicoside or its excipients. Additionally, oral formulations are contraindicated for individuals with certain hereditary metabolic disorders such as total lactase deficiency.

Age and Condition Restrictions

Systemic use of Miorel is not recommended for children and adolescents under 16 years of age. Eligibility is restricted to adults and adolescents 16 years and older for the short-term adjuvant treatment of painful muscle contractures associated with acute spinal pathology. The use must be strictly limited to a short duration. Caution is required for patients with a history of epilepsy or those with a risk of convulsions.

Interactions with other medicines and products

Regulatory documents outline specific interaction patterns for Thiocolchicoside, primarily involving pharmacodynamic effects and the risk of heightened organ toxicity, based on documented clinical experience.

---

Pharmacodynamic and Exposure-Risk Interactions

Substance Category	Officially Documented Interaction Pattern
Other Muscle Relaxants	Co-administration is not recommended due to the potential for a synergistic effect, increasing one another's impact.
CNS Sedative Agents	May develop a synergistic effect, potentially increasing central nervous system (CNS) depression and drowsiness.
NSAIDs and Paracetamol	Co-administration has been associated with reports of serious liver conditions, including fulminant hepatitis, indicating an exposure-risk altering pattern for hepatotoxicity.
Medicines Affecting Smooth Muscles	Caution is required due to a possible increase in the incidence rate of side effects related to effects on smooth muscles.

---

Absence of Documented Metabolic or Timing Interactions

Official prescribing information does not document specific interactions based on CYP enzyme inhibition or induction, nor are there documented interactions with known drug transporters. Furthermore, the regulatory labels do not mandate specific timing rules, such as requiring doses to be separated by a certain number of hours, for any co-administered products. While alcohol is generally advised to be avoided due to the enhanced CNS depressant effects, no specific food, herbal, or supplement interactions are explicitly restricted in the formal labeling.

How Miorel (Thiocolchicoside) Works

---

Modulating Inhibitory Signals in the Central Nervous System

Thiocolchicoside primarily exerts its pharmacodynamic action on the Central Nervous System (CNS), particularly within the spinal cord and brainstem. The molecule functions by interacting with and enhancing the inhibitory effects of key chemical messengers, GABA (Gamma-aminobutyric acid) and Glycine. It acts as a Glycine receptor agonist and, at higher concentrations, as a positive allosteric modulator of GABA-A receptors. This interaction increases the inhibitory signal transmission in the CNS pathways.

---

Decreasing Alpha-Motor Neuron Excitability

The enhancement of central inhibitory pathways leads to a suppression of excessive excitatory impulses originating from the CNS. By decreasing the excitability of alpha-motor neurons (nerves innervating skeletal muscles), the mechanism results in a physiological reduction of hypertonia (excessive muscle tone). Furthermore, this action modulates nociceptive signal transmission at the spinal level without exerting any direct effect on the peripheral muscle fibers.

How to Use Miorel (Thiocolchicoside) — Administration Guidelines

Thiocolchicoside (often marketed as Miorel) must be used strictly according to the administration and dosing instructions. The instructions define the ways the medicine is taken, the correct dosage, and the mandatory limits on the duration of treatment.

---

Approved Routes and Forms

Thiocolchicoside is available for two approved routes of administration:

• Oral Use: Administered as hard capsules or tablets (e.g., 4 mg or 8 mg strength).
• Intramuscular (IM) Use: Administered as a solution for injection (e.g., 4 mg/2 ml), typically by a healthcare professional.

Standard Dosing and Frequency

Treatment must be limited to the lowest effective dose for the shortest possible duration. The dosage must not exceed the stated limits, and the medicine is generally taken twice daily (every 12 hours).

Route of Administration	Single Dose	Maximum Daily Dose	Frequency
Oral Form	8 mg	16 mg	Twice Daily
IM Form	4 mg	8 mg	Twice Daily

Special Administration Conditions and Limits

Duration of Use: The treatment duration is strictly limited and must be discontinued after the specified period.

• Oral treatment: Maximum of 7 consecutive days.
• Intramuscular treatment: Maximum of 5 consecutive days.

Age Restrictions: Thiocolchicoside is not recommended and must not be used in children and adolescents under 16 years of age.

Taking Oral Forms: Oral tablets or capsules should be swallowed whole with a glass of water.

Research Evidence / Overview of Studies

---

Mechanisms of Action

Studies investigated the compound's actions, which include potential interaction with gamma-aminobutyric acid (GABA) and glycine receptors in the central nervous system. Laboratory research focused on a specific biological pathway associated with muscle tone.

---

Clinical Efficacy Research

Research has evaluated the compound for use in individuals with acute painful muscle contractures, particularly those related to spinal pathology. The overall certainty of evidence is considered very low for efficacy in musculoskeletal pain.

• Primary Studies: A systematic review and meta-analysis of randomized controlled trials (RCTs) found that the compound led to statistically significant reductions in patient-reported pain intensity scores (Visual Analogue Scale or VAS) over 2 to 7 days of treatment, particularly for acute low back pain.

  • However, the magnitude of the reduction was found to be very small, with pooled effect estimates remaining below the Minimally Important Difference (MID) that patients typically perceive as beneficial.

• Combination Evaluation: Research examined whether combining the compound with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) resulted in different outcomes for acute low back pain. Some studies suggest that the combination may lead to a greater reduction in pain intensity and functional improvement compared to NSAIDs alone.

---

Safety and Tolerability Profile

The studies documented a range of adverse events, including those classified as mild and moderate, such as gastrointestinal discomfort and drowsiness. Recent regulatory warnings emphasize that one of the compound's metabolites has shown the potential for aneuploidy (a chromosomal abnormality) in preclinical studies.

• Duration of Use: As a precautionary measure, use of the compound is typically restricted to short-term treatment (e.g., no more than 7 days orally) for acute conditions only.
  • The use is contraindicated in pregnant women, during lactation, and in women of childbearing potential not using effective contraception, due to potential risks.

---

Summary of Research Findings

The compiled research data allows for further investigation into the compound's potential application as an adjuvant treatment for muscle contractures, balanced against significant regulatory and safety concerns.

Key Studies & References

1. Efficacy and Safety of the Combination of Diclofenac and Thiocolchicoside in the Treatment of Low Back Pain and Other Conditions: Systematic Review of the Literature

Common questions about Miorel (Thiocolchicoside) (FAQ)

Q: Can I drink alcohol while taking this medicine?

A: Official regulatory documents indicate that combining this medicine with alcohol may increase certain side effects, such as sleepiness and dizziness. This combination can also impact mental function and judgment, making activities requiring mental alertness, such as driving or operating heavy machinery, potentially hazardous.

---

Q: Does this medicine make you sleepy or affect your concentration?

A: Yes, official product information indicates this medicine may cause dizziness and somnolence (sleepiness). Additionally, some patients have reported experiencing difficulty with concentration or attention. Consequently, the ability to perform skilled tasks, such as driving or operating heavy machinery, may be reduced while taking this medicine.

---

Q: Is it safe to take this for an extended period, or is it only for short-term use?

A: Official product information does not specify a maximum duration of use for this medicine. However, the regulatory documents include information on potential issues associated with both starting and chronic (long-term) treatment. This includes the possibility of withdrawal symptoms if the medicine is abruptly discontinued after an extended period of use.

---

Q: What is the recommended storage temperature for the capsules?

A: According to the official product information, the capsules should be stored at 25°C (77°F). Temporary temperature changes are usually permitted within a certain range, typically between 15°C and 30°C (59°F and 86°F).

---

Q: Can children 2 years old use this medicine?

A: Official regulatory labels state that use in pediatric patients is indicated for specific conditions, such as adjunctive therapy for partial-onset seizures starting from 1 month of age and older. Use for children is restricted to specific indications and age ranges outlined in the official labeling and is generally based on the child's weight.

---

Q: Can I take this medicine if I'm pregnant or breastfeeding?

A: For pregnancy, official information notes that there are no adequate and controlled studies in pregnant women, and animal studies suggest potential risks to the developing fetus. Official labeling advises women of childbearing potential to use effective contraception. For breastfeeding, the medicine passes into human milk, and the official product information recommends against breastfeeding while using this medicine.

---

Q: What should I do if I forget to take a dose?

A: Regulatory guidance states that if a dose is missed, it should be taken as soon as remembered. However, if it is close to the next scheduled dose, the label suggests skipping the missed one and taking the next dose at the regular time. The guidance also cautions against taking two doses at the same time to compensate for a missed dose.

Storage and Disposal of Miorel (Thiocolchicoside)

The medicine's stability requires strict adherence to documented regulatory storage conditions. Miorel (Thiocolchicoside) must be stored below 30 C and must not be frozen. It is mandatory to keep the product in its original packaging and protect it from light and moisture.

Child Safety and Waste Handling

All formulations must be securely kept out of the sight and reach of children.

For disposal, do not use the medicine after the expiry date printed on the package. Unused or expired Miorel must not be thrown away via wastewater or household waste. It must be disposed of according to local requirements, typically by consulting a pharmacist for guidance on medicine take-back programs.